Official Title ExaStim Upper Limb Pivotal Clinical Validation Study

Purpose

The purpose of this study is to evaluate the safety and effectiveness of ExaStim® transcutaneous spinal stimulation on upper extremity function when applied in combination with physical therapy (PT) and/or occupational therapy (OT).

Participants will be randomized to the stimulation group or a control group. Outcomes will include sensory, motor, and functional tests, as well as questionnaires.

Could this study be right for you?

• Aged 22 years or older
• Traumatic chronic spinal cord injury
• Level of injury between C2-T2
• No active implanted medical device for electrical stimulation
• No Botox for 3 months
• Have a chronic, traumatic SCI (chronic is >12 months since injury, or 6 months if unchanged symptoms)
• Has some, but limited upper extremity function
• BMI <40
• Cannot be pregnant

Age Range

22 years and up

Official Title Treatment of Stress and Anxiety in mild cognitive impairment (MCI)/Mild Alzheimer's Disease and related dementias (ADRD) and their care partners: A Randomized Controlled Trial

Purpose

The purpose of this study is to assess the impact of a treatment on anxiety and stress in individuals with memory concerns and those already with a diagnosis of Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease and related dementias. 

Could this study be right for you?

The primary participant must:

• Be at least 60 years of age
• Have a “care-partner” that is willing to participate in the full program (such as a spouse, child or a good friend)
• NOT have a terminal illness or severe motor impairment
• Be able to use a computer and smartphone and read English at the 6th grade level

The care partner must:

• Be at least 18 years of age
• Be able to use a computer and smartphone and read English at the 6th grade level

Age Range

60 - 99 years

Official Title Dilated Wavefront versus Non-Dilated Wavefront for Metric-Optimized Refraction Procedure for Individuals with Down Syndrome

Purpose

The purpose of this study is to examine whether we can use an instrument that measures how the eye focuses light to determine the best glasses prescription.

Could this study be right for you?

• Children with Down syndrome age 5 to 17 years
• Able to do vision tests by naming or matching shapes or letters
• Able to look at lights for short periods of time
• No nystagmus (uncontrolled eye movements when trying to look at things)
• Safe to dilate the eyes - we will screen medical history, eye health, and allergies to determine this
• No scars on the front of the eye
• No cataracts
• No eye diseases like glaucoma or retinal problems

Age Range

5 - 17 years

Official Title A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Purpose

The purpose of this study is to see if benralizumab (biologic drug), given as injections under the skin, can help control your Hypereosinophilic Syndrome (HES) better if it is added to available standard of care HES medications which you may be currently taking. 

HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction.

The duration of the study will last 18 months.

Could this study be right for you?

• Eosinophil (a type of white blood cells) count ≥ 1000 cells/μL at screening
• Documented diagnosis of Hypereosinophilic Syndrome (HES)
• History of persistent eosinophilia >1500 cells/μL (at least 2 examinations, interval ≥1 month)
• End organ manifestations attributable to the eosinophilia

Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

18 years and up

Official Title Retirement from contact sports after concussion

Purpose

The purpose of this study is to learn about the experiences of children and young adults after they stop playing contact sports due to concussion.

Could this study be right for you?

• Male and females aged 14-22 years old
• Retired from contact sports due to prior concussion

Additionally, a parent may participate if their child enrolls.

Age Range

14 - 22 years

Official Title Retirement from Contact Sports after Concussion

Purpose

The purpose of this study is to understand the experiences of children and young adults after medical retirement from contact sports due to concussion(s).

Participants and their parent(s) will complete online questionnaires (about 10 minutes) at the time of enrollment. You will then be scheduled for an interview (about 30 minutes) by video meeting or phone.

Could this study be right for you?

• Children and young adults who have retired from contact sports or other high-risk activities (i.e. dirt bike riding, downhill skiing...) due to prior concussion.  
• Parents may participate if their child enrolls.

Age Range

14 - 22 years

Official Title Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC), pregnant woman

Purpose

This study involves evaluating a medication for hepatitis C in pregnant women. 

If you are a pregnant woman with chronic hepatitis C and you join the study, you are consenting to enroll yourself and your baby after he/she is born.

Maternal participants will have 7 visits over approximately 7 months. Infant participants have four visits over approximately the first year of life.

Could this study be right for you?

(This is not a complete list)  

• Must be 18 - 45 years of age
• Chronic HCV infection of at least 6 months
• Singleton pregnancy at 20 + 0 to 30 + 0 weeks’ gestation
• Documented negative Hepatitis B testing for current infection (negative HBsAg test) prior to enrollment
• If living with HIV, must be on antiretroviral therapy

Exclusion Criteria (not a complete list)

• Plans to relocate away from the study site area in the next 16 months and unable/unwilling to return for study visits
• History of cirrhosis
• Known fetal chromosomal abnormality prior to enrollment

Age Range

18 - 45

Official Title Evaluating the effect of a WearIng a TENS-device in NausEa Relief (The WINNER Study)

Purpose

The purpose of this study is to evaluate if this wearable device can help manage nausea in those who suffer from this problem chronically. 

If you choose to participate, then you will be given the study device to wear on your wrist for 12 weeks. In the weeks before and during this time, you will complete a series of daily and weekly questionnaires about your nausea symptoms, mood, sleep, and bowel habits.

Could this study be right for you?

• Nausea going on for more than 2 months
• 18 years or older
• Able to understand English
• Seen at OSU for their care
• Able to complete surveys online using either smartphone or computer

Age Range

18 and up

Official Title Orexin Receptor Antagonists as Modulators of Threat Sensitivity in individuals with Alcohol Use Disorder

Purpose

The purpose of this study is to see if BELSOMRA, an FDA approved medication that is prescribed to treat insomnia, changes the body’s response to stress. Participation in the study includes 3 or 5 in-person lab visits (depending on randomization), which include EEG and MRI. Nearly all visits are 1.5 hours long, with the exception of one that is 4-5 hours in duration. Visits are flexible and scheduled at your convenience. Participants take the medication (or placebo) for 4 weeks, during which participation is only composed of virtual surveys via a smartphone app.

The total length of participation in the study is 1.5-2 months depending on scheduling/availability.

Could this study be right for you?

Eligibility Criteria:

• 18-65 years old
• Generally medically and physically healthy
• Regular alcohol use

Exclusion Criteria:

• Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
• Currently pregnant or trying to become pregnant (female)
• Presence of ferrous-containing metal in the body
• Inability to tolerate enclosed spaces

Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

18 - 65

Official Title A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of AAV2-BDNF [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor] in Subjects with Early Alzheimer’s Disease and Mild Cognitive Impairment

Purpose

The primary aim of this study is to determine whether administration of the nervous system growth factor "Brain-Deruved Neurotrophic Factor" (BDNF) to eligible patients with Alzheimer's disease and Mild Cognitive Impairment is safe and tolerable. This study will be used to determine whether BDNF administration reduces neuronal loss and rebuilds synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). 

Could this study be right for you?

• Male and Females aged 50 years or older
• Diagnosis of dementia due to Alzheimer's Disease/Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease
• A caregiver is available who has frequent contact with the subject, agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol
• CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal 

Inclusion Criteria varies, please contact Study Coordinator for more information.

The below Exclusion Criteria apply to both the AD and MCI groups.

• Any significant neurological disease other than suspected incipient disease
• History of schizophrenia 
• History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
• Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol
• Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to screening.

Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

50 and up

Official Title An Intervention Study about Primary Care Algorithms for Early Identification of Young Women with von Willebrand Disease

Purpose

Researchers at Nationwide Children’s Hospital are seeking volunteers to be a part of a study looking at how to best screen for bleeding disorders in young women.

Participants will be asked to complete questionnaires. If their survey answers suggest they have heavy menses or abnormal bleeding, they will also be asked to have a blood draw on the same day.

Could this study be right for you?

• Are 9 to 21 years old
• Have had your first menstrual cycle

Age Range

9 - 21

Official Title FASED (Footstool in Alleviating Symptoms of Evacuation Disorder)

Purpose

The purpose of this research study is to see if using a footstool can make it easier to have bowel movements in patients who suffer from chronic constipation. The participants will be given a free footstool to use. They will be asked to keep a record of their bowel symptoms and answer some surveys about their symptoms on a phone or computer. 

You will be in the study for approximately 12 weeks. This includes 2 weeks before you start using the footstool, followed by 8 weeks where you will be using the footstool and up to 2 weeks to complete your initial and final surveys. 

Could this study be right for you?

• At least 18 years old
• Able to understand English
• Symptoms such as feeling incompletely empty after a bowel movement, needing to strain a lot when having a bowel movement or needing to use maneuvers such as rocking one's body back and forth or using their finger to remove stool.

Age Range

18 - 99